Patient leaflet - Erlotinib 150 mg film-coated tablets
1. WHAT ERLOTINIB IS AND WHAT IT IS USED FOR
Erlotinib contains the active substance erlotinib. Erlotinib is a medicine used to treat cancer by preventing the activity of a protein called epidermal growth factor receptor (EGFR). This protein is known to be involved in the growth and spread of cancer cells.
Erlotinib is indicated for adults. This medicine can be prescribed to you if you have non-small cell lung cancer at an advanced stage. It can be prescribed as initial therapy or as therapy if your disease remains largely unchanged after initial chemotherapy, provided your cancer cells have specific EGFR mutations. It can also be prescribed if previous chemotherapy has not helped to stop your disease.
This medicine can also be prescribed to you in combination with another treatment called gemcitabine if you have cancer of the pancreas at a metastatic stage.
2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE ERLOTINIB
Do not take Erlotinib:
if you are allergic to erlotinib or any of the ingredients of this
medicine (listed in section 6).
Warnings and precautions:
if you are taking other medicines that may increase or
decrease the amount of erlotinib in your blood or influence its effect (for example antifungals like ketoconazole, protease inhibitors, erythromycin, clarithromycin, phenytoin, carbamazepine, barbiturates, rifampicin, ciprofloxacin, omeprazole, ranitidine, St. John’s Wort or proteasome inhibitors), talk to your doctor. In some cases these medicines may reduce the efficacy or increase the side effects of Erlotinib and your doctor may need to adjust your treatment. Your doctor might avoid treating you with these medicines while you are receiving Erlotinib.
if you are taking anticoagulants (a medicine which helps to
prevent thrombosis or blood clotting e.g. warfarin), Erlotinib may increase your tendency to bleed. Talk to your doctor, he will need to regularly monitor you with some blood tests.
if you are taking statins (medicines to lower your blood
cholesterol), Erlotinib may increase the risk of statin related muscle problems, which on rare occasions can lead to serious muscle breakdown (rhabdomyolysis) resulting in kidney damage, talk to your doctor.
if you use contact lenses and/or have a history of eye
problems such as severe dry eyes, inflammation of the front part of the eye (cornea) or ulcers involving the front part of the eye, tell your doctor.
See also below “Other medicines and Erlotinib”
You should tell your doctor:
if you have sudden difficulty in breathing associated with
cough or fever because your doctor may need to treat you with other medicines and interrupt your Erlotinib treatment;
if you have diarrhoea because your doctor may need to treat
you with anti-diarrhoeal (for example loperamide);
immediately, if you have severe or persistent diarrhoea,
nausea, loss of appetite, or vomiting because your doctor may need to interrupt your Erlotinib treatment and may need to treat you in the hospital;
- If you have ever had problems with your liver. Erlotinib may cause serious liver problems and some cases have been fatal. Your doctor may perform blood tests while you are taking this medicine to monitor whether your liver functions properly.
- if you have severe pain in the abdomen, severe blistering or peeling of skin. Your doctor may need to interrupt or stop your treatment;
- if you develop acute or worsening redness and pain in the eye, increased eye watering, blurred vision and/or sensitivity to light, please tell your doctor or nurse immediately as you may need urgent treatment (see Possible Side Effects below).
- if you are also taking a statin and experience unexplained muscle pain, tenderness, weakness or cramps. Your doctor may need to interrupt or stop your treatment. See also section 4 “Possible side effects”.
Liver or kidney disease
It is not known whether Erlotinib has a different effect if your liver or kidneys are not functioning normally. The treatment with this medicine is not recommended if you have a severe liver disease or severe kidney disease.
Glucuronidation disorder like Gilbert’s syndrome Your doctor must treat you with caution if you have a glucuronidation disorder like Gilbert’s syndrome. Smoking
You are advised to stop smoking if you are treated with Erlotinib as smoking could decrease the amount of your medicine in the blood.
Children and adolescents
Erlotinib has not been studied in patients under the age of 18 years. The treatment with this medicine is not recommended for children and adolescents.
Other medicines and Erlotinib
Tell your doctor or pharmacist if you are taking, have recently taken any other medicines or might take any other medicines. Erlotinib with food and drink
Do not take Erlotinib with food. See also section 3 ‘How to take Erlotinib’
Pregnancy and breast-feeding
Avoid pregnancy while being treated with Erlotinib. If you could become pregnant, use adequate contraception during treatment, and for at least 2 weeks after taking the last tablet. If you become pregnant while you are being treated with Erlotinib, immediately inform your doctor who will decide if the treatment should be continued.
Do not breast-feed if you are being treated with Erlotinib, and for at least 2 weeks after taking the last tablet.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Driving and using machines
Erlotinib has not been studied for its possible effects on the ability to drive and use machines but it is very unlikely that your treatment will affect this ability.
Hypersensitivity
Erlotinib contains a sugar called lactose monohydrate and sodium.
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking Erlotinib. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.
3. HOW TO TAKE ERLOTINIB
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. The tablet should be taken at least one hour before or two hours after the ingestion of food.
The usual dose is one tablet of Erlotinib 150 mg each day if you have non-small cell lung cancer.
The usual dose is one tablet of Erlotinib 100 mg each day if you have metastatic pancreatic cancer.
Erlotinib is given in combination with gemcitabine treatment. Your doctor may adjust your dose in 50 mg steps. For the different dose regimens Erlotinib is available in strengths of 25 mg, 100 mg or 150 mg.
If you take more Erlotinib than you should
Contact your doctor or pharmacist immediately.
You may have increased side effects and your doctor may interrupt your treatment.
If you forget to take Erlotinib
If you miss one or more doses of Erlotinib, contact your doctor or pharmacist as soon as possible.
Do not take a double dose to make up for a forgotten dose. If you stop taking Erlotinib
As stated in design
Package leaflet
160 x 370 mm
TBA
TW263181 (MAT)
UK
[All]
NA
TBA
9 points (Reg text)
NA - new 23/04/2026
Black C
It is important to keep taking Erlotinib every day, as long as your doctor prescribes it for you.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
4. POSSIBLE SIDE EFFECTS
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Contact your doctor as soon as possible if you suffer from any of the below side effects. In some cases your doctor may need to reduce your dose of Erlotinib or interrupt treatment:
Diarrhoea and vomiting (very common: may affect more than
1 out of 10 people). Persistent and severe diarrhoea may lead to low blood potassium and impairment of your kidney function, particularly if you receive other chemotherapy treatments at the same time. If you experience more severe or persistent diarrhoea contact your doctor immediately as your doctor may need to treat you in the hospital.
Eye irritation due to conjunctivitis/keratoconjunctivitis (very
common: may affect more than 1 out of 10 people) and keratitis (common: may affect up to 1 in 10 people).
Form of lung irritation called interstitial lung disease
(uncommon in European patients; common in Japanese patients: may affect up to 1 in 100 people in Europe and up to 1 in 10 in Japan). This disease can also be linked to the natural progression of your medical condition and can have a fatal outcome in some cases. If you develop symptoms such as sudden difficulty in breathing associated with cough or fever contact your doctor immediately as you could suffer from this disease. Your doctor may decide to permanently stop your treatment with Erlotinib.
Gastrointestinal perforations have been observed
(uncommon: may affect up to 1 in 100 people). Tell your doctor if you have severe pain in your abdomen. Also, tell your doctor if you had peptic ulcers or diverticular disease in the past, as this may increase this risk.
In rare cases inflammation of the liver (hepatitis) was
observed (may affect up to 1 in 1,000 people). Symptoms may include a general feeling of being unwell, with or without possible jaundice (yellowing of the skin and eyes), dark urine, nausea, vomiting and abdominal pain. In rare cases liver failure was observed. This can potentially be fatal. If your blood tests indicate severe changes in your liver function, your doctor may need to interrupt your treatment. Very common side effects (may affect more than 1 in 10 people):
Rash which may occur or worsen in sun exposed areas. If
you are exposed to sun, protective clothing, and/or use of sunscreen (e.g. mineral-containing) may be advisable
- Infection
- Loss of appetite, decreased weight
- Depression
Headache, altered skin sensation or numbness in the
extremities
- Difficulty in breathing, cough
- Nausea
- Mouth irritation
- Stomach pain, indigestion and flatulence
- Abnormal blood tests for the liver function
- Itching, dry skin and loss of hair
- Tiredness, fever, rigors
Common side effects (may affect up to 1 in 10 people):
- Bleeding from the nose
- Bleeding from the stomach or the intestines
- Inflammatory reactions around the fingernail
- Infection of hair follicles
- Acne
- Cracked skin (skin fissures)
Reduced kidney function (when given outside the approved
indications in combination with chemotherapy) Uncommon side effects (may affect up to 1 in 100 people):
- Eyelash changes
- Excess body and facial hair of a male distribution pattern
- Eyebrow changes
- Brittle and loose nails
Rare side effects (may affect up to 1 in 1,000 people):
Flushed or painful palms or soles (Palmar plantar
erythrodysaesthesia syndrome)
Very rare side effects (may affect up to 1 in 10,000 people):
- Cases of perforation or ulceration of the cornea
Severe blistering or peeling of skin (suggestive of Stevens-
Johnson syndrome)
Inflammation of the coloured part of the eye
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme, website www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
5. HOW TO STORE ERLOTINIB
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the blister and the carton after EXP.
The expiry date refers to the last day of that month. This medicine does not require any special storage conditions. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
6. CONTENTS OF THE PACK AND OTHER INFORMATION
What Erlotinib contains:
- The active substance of Erlotinib is erlotinib. Each film-coated tablet contains 25 mg, 100 mg or 150 mg of erlotinib (as erlotinib hydrochloride) depending on the strength.
The other ingredients are:
Tablet core: cellulose microcrystalline, lactose monohydrate, sodium starch glycolate, sodium laurilsulfate, magnesium stearate
Tablet coat: hydroxypropyl cellulose, hypromellose, titanium dioxide, propylen glycol.
What Erlotinib looks like and contents of the pack:
Erlotinib 25 mg film-coated tablets
White coloured, round shaped (6.50 mm in diameter), biconvex, film-coated tablets, debossed with “E 25” on one side and plain on other side.
Erlotinib 100 mg film-coated tablets
White coloured, round shaped (8.90 mm in diameter), biconvex, film-coated tablets, debossed with “E 100” on one side and plain on other side.
Erlotinib 150 mg film-coated tablets
White coloured, round shaped (10.50 mm in diameter), biconvex, film-coated tablets, debossed with “E 150” on one side and plain on other side.
Clear PVC-Al blister containing 30 tablets.
Marketing Authorisation Holder
Tillomed Laboratories Limited
220 Butterfield, Great Marlings
Luton, LU2 8DL, United Kingdom
Manufacturer
Manx Healthcare Limited
Taylor Group House
Wedgnock Lane
Warwick
CV34 5YA
United Kingdom
Other formats
To request a copy of this leaflet in Braille, large print or audio, please call 0800 970 6115.
This leaflet was last revised in April 2026.
Material code(s)